1270077-79-6

Basic information

• Product Name: (R)-3-[5'-chloro-6-(cyclohexylmethylamino)-[2,4,]bipyridinyl-2'-ylcarbamoyl]piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: (R)-3-[5'-chloro-6-(cyclohexylmethylamino)-[2,4,]bipyridinyl-2'-ylcarbamoyl]piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1270077-79-6
• Molecular Weight: 528.094
• Mol File: 1270077-79-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (R)-3-[5'-chloro-6-(cyclohexylmethylamino)-[2,4,]bipyridinyl-2'-ylcarbamoyl]piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-[5'-chloro-6-(cyclohexylmethylamino)-[2,4,]bipyridinyl-2'-ylcarbamoyl]piperidine-1-carboxylic acid tert-butyl ester(1270077-79-6)
• EPA Substance Registry System: (R)-3-[5'-chloro-6-(cyclohexylmethylamino)-[2,4,]bipyridinyl-2'-ylcarbamoyl]piperidine-1-carboxylic acid tert-butyl ester(1270077-79-6)

Safety Data

• Hazardous Substances Data: 1270077-79-6(Hazardous Substances Data)

Upstream product

• 1269754-97-3 (R)-tert-butyl 3-(5-chloro-4-iodopyridin-2-ylcarbamoyl)piperidine-1-carboxylate 
• 1260667-65-9 5-chloro-4-iodo-pyridin-2-amine 
• 842136-58-7 2-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 659731-48-3 5-chloro-2-fluoro-4-iodopyridine 
• 144100-07-2 2-bromo-6-fluoropyridine 
• 1270077-44-5 (R)-tert-butyl 3-(5'-chloro-6-fluoro-2,4'-bipyridin-2'-ylcarbamoyl)piperidine-1-carboxylate 
• 3218-02-8 cyclohexylmethylamine 

Relevant articles and documents

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.